Lewis F Neville, Itamar Shalit, Peter A Warn, Marc H Scheetz, Jiuzhi Sun, Madeline B Chosy, Paul A Wender, Lynette Cegelski, Jacob T Rendell
Antimicrobial agents and chemotherapy 2021 Mar 18The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC towards Escherichia coli, including β-lactamase expressing Ambler classes A, B, and D, was 8 to 16 μg/ml. Addition of 8 times the MIC of V-r to E. coli was acutely bactericidal and associated with a low frequency of resistance (<2.32 × 10-10). In vivo, V-r markedly reduced E. coli burden by >7 log10 CFU/g in a thigh muscle model. These data warrant further development of V-r in combatting E. coli, including resistant forms. Copyright © 2021 Neville et al.
Lewis F Neville, Itamar Shalit, Peter A Warn, Marc H Scheetz, Jiuzhi Sun, Madeline B Chosy, Paul A Wender, Lynette Cegelski, Jacob T Rendell. In Vivo Targeting of Escherichia coli with Vancomycin-Arginine. Antimicrobial agents and chemotherapy. 2021 Mar 18;65(4)
PMID: 33468474
View Full Text